These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24838323)

  • 21. Significance and possible causes of false-negative results of reflex human Papillomavirus infection testing.
    Eltoum IA; Chhieng DC; Crowe DR; Roberson J; Jin G; Broker TR
    Cancer; 2007 Jun; 111(3):154-9. PubMed ID: 17477380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening.
    Wei B; Mei P; Huang S; Yu X; Zhi T; Wang G; Xu X; Xiao L; Dong X; Cui W
    Virol J; 2020 Nov; 17(1):171. PubMed ID: 33168022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.
    Qiao YL; Sellors JW; Eder PS; Bao YP; Lim JM; Zhao FH; Weigl B; Zhang WH; Peck RB; Li L; Chen F; Pan QJ; Lorincz AT
    Lancet Oncol; 2008 Oct; 9(10):929-36. PubMed ID: 18805733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and surface plasmon resonance for genotyping of high-risk human papillomaviruses.
    Qu S; Huang J; Zhao J; Zhao X; Deng H; Yang H; Chen W; Liu L; Zhang L; Gao S
    Intervirology; 2011; 54(6):326-32. PubMed ID: 21242664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of screening performance of HPV DNA test on specimens from different sites of the female genital tract].
    Zhang S; Kang L; Liu B; Cui J; Chen F; Liu X; Wang H; Chen W
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):389-93. PubMed ID: 25030599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
    Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
    Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type-specific human papillomavirus DNA testing with the genotyping array: a comparison of cervical and vaginal sampling.
    Twu NF; Yen MS; Lau HY; Chen YJ; Yu BK; Lin CY
    Eur J Obstet Gynecol Reprod Biol; 2011 May; 156(1):96-100. PubMed ID: 21288625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
    Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
    Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
    J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology.
    Geraets DT; Heideman DA; de Koning MN; Snijders PJ; van Alewijk DC; Meijer CJ; van Doorn LJ; Quint WG
    J Clin Virol; 2009 Nov; 46 Suppl 3():S21-6. PubMed ID: 20129070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
    Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
    Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.
    Arbyn M; Roelens J; Cuschieri K; Cuzick J; Szarewski A; Ratnam S; Reuschenbach M; Belinson S; Belinson JL; Monsonego J
    Int J Cancer; 2013 Jan; 132(1):101-8. PubMed ID: 22610699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted next generation sequencing panel for HPV genotyping in cervical cancer.
    Lippert J; Bønløkke S; Utke A; Knudsen BR; Sorensen BS; Steiniche T; Stougaard M
    Exp Mol Pathol; 2021 Feb; 118():104568. PubMed ID: 33171155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
    Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
    Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical performance of the HPV DNA Array genotyping assay in detection of CIN2+ lesions with BS GP5+/6+ MPG Luminex tested cervical samples.
    Pesic A; Krings A; Hempel M; Preyer R; Kaufmann AM
    J Med Virol; 2020 Jan; 92(1):113-118. PubMed ID: 31471920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
    Cook DA; Mei W; Smith LW; van Niekerk DJ; Ceballos K; Franco EL; Coldman AJ; Ogilvie GS; Krajden M
    BMC Cancer; 2015 Dec; 15():968. PubMed ID: 26674353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.